Scarica l'app Stockscreener
0.7249
0.15%
0.0011
Precedente Chiudi:
$0.7238
Aprire:
$0.73
Volume 24 ore:
120.37K
Relative Volume:
0.76
Capitalizzazione di mercato:
$54.62M
Reddito:
$9.53M
Utile/perdita netta:
$-44.61M
Rapporto P/E:
-0.7966
EPS:
-0.91
Flusso di cassa netto:
$-38.32M
1 W Prestazione:
-7.03%
1M Prestazione:
-6.94%
6M Prestazione:
-41.78%
1 anno Prestazione:
-58.34%
Intervallo 1D:
$0.72
$0.7514
Intervallo di 1 settimana:
$0.675
$0.7797
Portata 52W:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Nome
Cue Biopharma Inc
Settore
Industria
Telefono
617-949-2680
Indirizzo
40 GUEST STREET, BOSTON, MA
Confronta CUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7249 | 58.75M | 9.53M | -44.61M | -38.32M | -0.91 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-13 | Iniziato | Jefferies | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2022-11-21 | Iniziato | Piper Sandler | Overweight |
| 2022-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-03 | Iniziato | Craig Hallum | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-04-09 | Iniziato | Stifel | Buy |
| 2020-01-28 | Iniziato | BTIG Research | Buy |
| 2020-01-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Cue Biopharma Inc Borsa (CUE) Ultime notizie
Stifel Financial Corp Grows Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Transcript : Cue Biopharma, Inc.Special Call - marketscreener.com
Cue Biopharma Inc Reports Q1 2025 Earnings: EPS of -$0.17 Misses Estimate, Revenue Falls Short at $0.4 Million - GuruFocus
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates - MSN
Cue Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cue Biopharma (CUE) Reports Revenue Miss for Q1 2025 | CUE Stock News - GuruFocus
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma Reports Strategic Collaboration with Boehringer Ingelheim and Financial Results for Q1 2025 - Nasdaq
Cue Biopharma (CUE) Schedules Virtual Investor Event to Showcase Biologics Platform | CUE Stock News - GuruFocus
Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - The Manila Times
Cue Biopharma to Participate in Fireside Chat at the Citizens Li - GuruFocus
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - The Manila Times
Cue Biopharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
LPL Financial LLC Has $47,000 Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
CUECue Biopharma Inc Latest Stock News & Market Updates - Stock Titan
Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia
Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa
Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN
Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus
Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma
Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech
Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard
Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter
Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India
Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia
Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus
Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus
Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com
Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus
Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times
Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus
Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq
Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus
Cue Biopharma Inc Azioni (CUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):